The compound AP 11014, currently in advanced preclinical studies, specifically targets the TGFβ-1 mRNA and has been shown to significantly reduce TGFβ-1 secretion in multiple cancer cell lines, impeding TGF-β1-induced immunosuppression [6, 312, 313]. The gene discussed is TGFB1; the disease is cancer.